Patents

US 12622952 B2: Formulations comprising recombinant acid α-glucosidase

Granted
2026-05-12
Filed
2022-11-07 application 18053151
Type
Utility · 28 claims
Elsewhere
Google Patents ↗ · USPTO patent document ↗ · USPTO Patent Center record ↗

Abstract

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

Source: PTBLXML, file of 2026-05-12 (ipgb20260512.xml).

Assignees

AssigneeTypePlaceAlso on furp.orgSource
Amicus Therapeutics, Inc. 158 patentsUS company or organizationPhiladelphia, PAAMICUS THERAPEUTICS, INC. Form D issuer EXACT high confidence: identical full name and state
AMICUS THERAPEUTICS, INC. SEC filer EXACT medium confidence: identical full name, one of each nationally
PTBLXML, file of 2026-05-12

Inventors

InventorPlacePatentsPerson pageSource
Hing CharEast Brunswick, NJ6PTBLXML, file of 2026-05-12
Sergey TeslerMonroe, NJ8PTBLXML, file of 2026-05-12
Wendy SunderlandDoylestown, PA4PTBLXML, file of 2026-05-12
Enrique DilonéBasking Ridge, NJ6PTBLXML, file of 2026-05-12
Russell GotschallDoylestown, PA17PTBLXML, file of 2026-05-12
Hung V. DoNew Hope, PA33PTBLXML, file of 2026-05-12

CPC categories

SubclassCategoryFirst groupSource
A61KPreparations for medical, dental or toiletry purposesA61K38/47PTBLXML, file of 2026-05-12
C12NMicroorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture mediaC12N9/2408PTBLXML, file of 2026-05-12
C12YEnzymesC12Y302/0102PTBLXML, file of 2026-05-12

Cooperative Patent Classification, as currently assigned (one row per subclass).

Assignments and security interests

RecordedWhatFromToReel/frameSource
2026-04-27Release of security interest
Release of security interest
WILMINGTON TRUST, NATIONAL ASSOCIATION signed 2026-04-27AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA75494/30PASDL, file of 2026-08-13
2026-04-27Security interest Security interest
Security interest
BIOMARIN PHARMACEUTICAL INC. signed 2026-04-27
AMICUS THERAPEUTICS, INC. signed 2026-04-27
CITIBANK, N.A., AS COLLATERAL AGENT NEW YORK, NY75493/968PASDL, file of 2026-10-15
2023-10-06Security interest Security interest
Security interest
AMICUS THERAPEUTICS, INC. signed 2023-10-05WILMINGTON TRUST, NATIONAL ASSOCIATION MINNEAPOLIS, MN65177/196PASDL, file of 2026-10-15
2023-01-16Assignment
Assignment of assignor's interest
CHAR, HING signed 2017-06-28
DILONE, ENRIQUE signed 2017-06-28
TESLER, SERGEY signed 2017-06-28
SUNDERLAND, WENDY signed 2017-06-28
AMICUS THERAPEUTICS, INC. PHILADELPHIA, PA62384/534PASDL, file of 2026-10-15

Documents recorded with the USPTO Assignment Recordation Branch that list this patent. A security interest is a lender’s claim on the patent as collateral; a release ends it.

USPTO bulk data: PatentsView granted patents, disambiguated (PVGPATDIS) for patents, assignees, inventors, places and CPC categories; the USPTO Patent Assignment Dataset (ECORSEXC) for assignments and security interests. Patents filed in the last 20 years. No claims or full text. Links to other records are by name (and state): EXACT means the identical full name and state; FUZZY means a looser name match, with the confidence shown.